Skip to main content
SpringerLink
Log in

Longer interval between last ICI dose and first TKI dose reduces risk of SAEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations Cancer Immunology Immunotherapy : 16 Apr 2023. Available from: URL: https://doi.org/10.1007/s00262-023-03429-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Longer interval between last ICI dose and first TKI dose reduces risk of SAEs. Reactions Weekly 1954, 10 (2023). https://doi.org/10.1007/s40278-023-37828-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-37828-0

Search

Navigation